Engineered immune cells aim to deepen remission in lymphoma patients
NCT ID NCT07587840
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new type of immunotherapy called CD19/CD22 CAR-T cells as an early consolidation treatment for people with follicular lymphoma who still have some disease after standard chemotherapy. About 20 participants will receive a single infusion of their own modified immune cells. The main goal is to see how many patients remain cancer-free one year after treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FOLLICULAR LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chinese PLA General Hospital
RECRUITINGBeijing, Beijing Municipality, 100853, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a cancer drug reboot the immune system after a stem cell transplant?
- Can a drug duo outsmart resistant lymphomas?
- Can a second CAR T-Cell infusion beat lymphoma that returns?
- New PET tracer could sharpen diagnosis of blood cancers
- 10,000 DNA samples could reveal hidden genetic triggers for leukemia and lymphoma
- New combo therapy aims to boost remission in Hard-to-Treat lymphoma